You are here:

Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance
Reference number: TA218
Published: 23 March 2011

Guidance
Tools and resources
Information for the public
History

MDS Patient Support Group, Leukaemia Society and Rare Cancer Forum

Appeals received
Initial scrutiny letter
Response to scrutiny letter
Final scrutiny letter
Response to final scrutiny letter
Response to final letter

This page was last updated: 27 May 2010